Objective To investigate the effect of decitabine on serum platelet derived growth factor levels in patients with leukemia. Methods 120 cases of acute myeloid leukemia patients admitted to our hospital from January 2012 to December 2014 were selected as the study subjects.The control group was given CAG regimen: 1-14 d Seventh days of intravenous infusion of 20 mg/d aclarubicin, first to fourteen days subcutaneous injection of 10 mg/m2 , 1 times per 12 h, 1-13 d cytosine arabinosine days under the subcutaneous injection of granulocyte colony stimulating factor 300μg/d.The observation group was given to the west of the lake 25 mg/d, intravenous infusion, used for 5 days.The levels of platelet derived growth factor PDGF in the two groups were compared and the therapeutic effect.Results Before treatment, differences of PDGF in control group and observation group was no statistical significance.After treatment, PDGF in observation group was lower than control group ( P <0.05).The proportion of primary cells of bone marrow of two groups after treatment was lower than before treatment, and the observation group was more lower.Total effective rate of observation group was 55.0%,which was higher than that in control group(35.0%)(P<0.05).Conclusion Decitabine could reduce the level of of PDGF in patients with leukemia, and improve the total effective rate.

Objective To study the effect of Shengmai injection on the platelet parameters and CD4+CD25+cells in peripheral blood of patients with chronic lymphocytic leukemia,and to explore the optimal regimen for patients with chronic lymphocytic leukemia.Methods One hundred and twenty patients with chronic lymphocytic leukemia were enrolled in this study from January 2012 to December 2014.(D1),vincristine 4mg(d1),prednisone 60 mg/d(d1-5)were given to the CHOP regimen in the control group: cyclophosphamide 600 mg/m2(d1),doxorubicin 25 mg/m2(d12)28d a course of treatment,a total of 4 courses,the observation group of patients in the control group of patients treated on the basis of Shengmai injection,compared the two groups of patients with chemotherapy,platelet parameters and serum CD4+CD25+T cells and Th17 cells.Results After treatment,the PLT,MPV and PDW of the observation group were(215.4± 31.7),(9.5±2.5)and(16.9±2.4),respectively,which were significantly higher than those of the control group.The CD4+CD25+T cells in the observation group were(1.5±0.8)The total effective rate of the control group was 35.0％,the total effective rate was 35.0％,and the total effective rate of the control group was 35.0％.There were significant difference between the control group and the control group(P<0.05),The difference was statistically significant.Conclusion Shengmai injection combined with CHOP regimen in chronic lymphocytic leukemia patients can improve immune function,promote platelet growth,improve platelet clinical parameters,and help improve the efficiency of chemotherapy,compared with CHOP alone Program treatment is better,worthy of clinical application.

Objective To evaluate the effectiveness of lamivudine in preventing liver damages and HBV DNA reactivation in anti-HBc positive lymphoma patients after chemotherapy.Methods Seventy-nine lymphoma patients who were negative in HBsAg and positive in anti-HBc were enrolled and were divided into lamivudine group (n=37) and control group (n=42).Both groups received chemotherapy.Liver damages and HBV reactivation were observed, and the data were analyzed with software SPSS 13.0.Results In lamivudine group, liver damages Ⅰ or Ⅱ was observed in 11 patients (11/37, 29.7%), and liver damages Ⅲ or Ⅳ was observed in 2 (2/37, 5.4%); two patients (2/37, 5.4%) developed HBV reactivation, and both of them had HBV YMDD mutations.In control group, 19 (19/42, 45.2%) patients experienced liver damages Ⅰ or Ⅱ, 7 (7/42, 16.7%) experienced liver damages Ⅲ or Ⅳ; 12 (12/42, 28.6%) patients experienced HBV reactivation, the differences between the two groups were of statistical significance (χ2=79.0, 8.7 and 79.0, P ＜ 0.05 or ＜ 0.01).Conclusion Lamivudine can reduce liver damages and HBV reactivation in HBsAg negative and anti-HBc positive patients with lymphoma during chemotherapy.

Objective To investigate the effect of L-asparaginase on the coagulation function of patients with acute lymphoblastic leukemia. Methods The general information of 100 patients with acute lymphoblastic leukemia from January 2013 to January 2017 admitted in the Department of Hematolog was retrospectively analyzed. All patients received no anticoagulation before chemotherapy. All patients were treated with routine treatment after admission, namely with vincristine + daunorubicin + prednisone induction therapy and then with VDLP regimen chemotherapy, combined with intravenous injection of L-asparaginase 8000 U/m2, once every other day. After 3 months of treatment, its clinical efficacy was evaluated, and adverse reactions during treatment were observed. The changes of coagulation indexes were compared before treatment and at 1 day and 7 days after treatment. Results Of the 100 patients, there were 22 cases of complete remission, 40 cases of partial remission, 26 cases of stable condition and 12 cases of progression, with total efficiency of 62％(62/100). During the treatment of 100 patients, 10 cases had allergy, 9 had a drop in white blood cell count, and 8 had gastrointestinal reactions including nausea and vomiting. On the first day after treatment, the levels of PT, APTT and TT in 100 patients were significantly higher than those before treatment, with significant difference (P＜ 0. 05 or P＜0. 01). However, the FIB level in patients was significantly lower than that before treatment, with significant difference (P＜0. 05). There were no significant differences between the levels of PT, APTT and TT in all patients at one week after treatment and those before treatment (P＞0. 05). Although FIB level in all patients at one week after treatment increased compared with that at one day after treatment, the difference had no significant difference. While the level of FIB was significantly lower than that before treatment, and the difference was significant (P＜0. 05). Conclusion L-asparaginase is effective and safe in the treatment of acute lymphoblastic leukemia, but it is easy to produce adverse reactions such as abnormal coagulation function. Therefore, the clinical application of L-asparaginase in the treatment of acute lymphoblastic leukemia should be dynamically monitored in patients in order to actively correct coagulation disorders, and the drug should be discontinued when necessary.